BeOne Medicines Ltd. (ONC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $373.36
- As of
Kresmion compiles this page from ONC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BeOne Medicines Ltd. (ONC): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-26.
See the full ONC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ONC on one page. Preview it with sample data, then open it live with a free account.
Preview the ONC dossierActive events for ONC
- high13F: funds added
4 tracked funds increased ONC this 2026Q2, institutional consensus
- highInsider cluster: sales
2 insiders at ONC sold $46.3M this week
- highInsider cluster: sales
14 insiders at ONC sold $46.3M this week
- high13F: large increase
CITADEL ADVISORS LLC added +9403% to ONC (2026Q2)
- high13F: funds added
3 tracked funds increased ONC this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every event on ONC, as it fires
You are seeing 5 of 19 events recorded on ONC since 2026-05-26.
The five above landed across 3 days. The other 14 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ONC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 07725L102 · 2026Q2 | $406.2M | 0.05% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 07725L102 · 2026Q2 | $154.8M | 0.06% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 07725L102 · 2026Q2 | $81.7M | 0.06% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 07725L102 · 2026Q2 | $29.1M | 0.04% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ONC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ONC against its peers
ONC's operating margin of 8.4% ranks in the 38th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ONC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.3B USD | 2.4B USD | 83 | 19 |
| Gross margin | 87.5% | 86.2% | 59 | 15 |
| Operating margin | 8.4% | 21.6% | 38 | 19 |
| Net margin | 5.4% | 14.9% | 36 | 20 |
| Return on equity | 6.6% | 11.2% | 40 | 20 |
| P / E | n/a | 31.1x | n/a | 11 |
| 1 year | n/a | 27.5% | n/a | 5 |
Peers (22): RVMD, BIIB, GMAB, ARGX, ALNY, NTRA, RPRX, ROIV, UTHR, INCY, BNTX, REGN, INSM, MRNA, EXEL, ASND, NBIX, HALO, BBIO, VRTX, SMMT, BMRN. Left out: CSLLY (no annual filing), IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ONC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ONC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ONC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.